Clinical Trials
119 trialsPembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Fujian Cancer Hospital
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
INTERACT-II
Catharina Ziekenhuis Eindhoven
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Shanghai Zhongshan Hospital
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Fudan University
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Zhejiang Cancer Hospital
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Fujian Medical University
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
ERASE-TMZ
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Zhejiang Cancer Hospital
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
First Affiliated Hospital of Wenzhou Medical University
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Zhejiang Cancer Hospital
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Khon Kaen University
Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
West China Hospital
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
BEYOND
Grupo Espanol Multidisciplinario del Cancer Digestivo
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
FOLFIRINOX + RT for Pancreatic Cancer
Massachusetts General Hospital
Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer
China Medical University, China
Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer
China Medical University, China
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
China Medical University, China
IRIGA
Blokhin's Russian Cancer Research Center
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
Fudan University
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
Fudan University
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix
Assiut University
A Single-arm, Phase â…¡ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
First People's Hospital of Hangzhou
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Guangdong Association of Clinical Trials
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer
Fudan University
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
Peking Union Medical College Hospital
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
Fudan University
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer
Fudan University
A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer
Fudan University
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
ChineseAMS